share_log

HC Wainwright & Co. Initiates Coverage On Reneo Pharmaceuticals With Buy Rating, Announces Price Target of $30

HC Wainwright & Co. Initiates Coverage On Reneo Pharmaceuticals With Buy Rating, Announces Price Target of $30

HC Wainwright & Co.以買入評級開始對瑞諾製藥進行報道,宣佈目標股價爲30美元
Benzinga ·  2023/08/28 06:15

HC Wainwright & Co. analyst Gobind Singh initiates coverage on Reneo Pharmaceuticals (NASDAQ:RPHM) with a Buy rating and announces Price Target of $30.

HC Wainwright&Co.分析師戈賓德·辛格以買入評級開始報道Reneo製藥公司(納斯達克代碼:RPHM),並宣佈目標價為30美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論